entertainment -WSS

entertainment

author：leisure time 2025-10-01 23:00:08 - browse：254

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Home health providers sue Medicare over payment cuts

WSS

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

AstraZeneca stays mum on Medicare drug pricing negotiations

The Biogen Aduhelm mess could happen again

Texas Medical Board asked to define abortion emergency exception

Medicare wants to send $9 billion to 340B hospitals

Biden’s NIH nominee is languishing in Congress

focus

entertainment

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

How to save PrEP access — and even expand it

Top private equity targets in 2023: cardiology, clinical trials, lasers

Jerome Adams on the need for new antivirals for Covid

Biden targets hefty hospital 'facility fees' that often surprise patients

BioMarin wins approval for gene therapy to treat hemophilia A

A protest over insulin prices is seen as a fight for life

In Memoriam: Notable people who died in 2023

340B reform proposal comes out of Senate working group

hotspot

Dozens of beaches across Northeast closed for swimming due to high levels of bacteria in water

Why Novartis is going to walk from its acquisition of MorphoSys

Why Novartis is going to walk from its acquisition of MorphoSys

A single Democrat is willing to weaken Medicare negotiation power

Texas Medical Board asked to define abortion emergency exception

Biden’s NIH nominee is languishing in Congress

knowledge

knowledge

knowledge

knowledge